Clover initiated gp120-Trimer (SCB-703) AIDS vaccine study

Clover initiated gp120-Trimer (SCB-703) AIDS vaccine study CHENGDU, CHINA, October 23, 2015 — Clover has initiated a gp120-Trimer (SCB-703) AIDS vaccine study with Covance USA and The Center for Aids Research (CFAR) of Duke University. Current progress made in AIDS vaccine research has revealed that native trimeric gp120 is the preferred antigen for eliciting broadly neutralizing antibodies (bNabs) and could hold promise for an effective prophylactic vaccine for the deadly disease. SCB-703 has retained the structure of the most native-like gp120 trimer without any internal mutations, unlike those found in previously studied trimeric constructs, such as SOSIP.664 gp140 trimer.

The release as fetched from its publisher. cloverbiopharma.com ↗